CRNX CRINETICS PHARMACEUTICALS INC Product Launches 8-K Filing 2023 - Phase 3 Study Results Crinetics Pharmaceuticals announced positive results from its Phase 3 study of paltusotine for acromegaly treatment, with plans to submit a new drug application in 2024.Get access to all SEC 8-K filings of the CRINETICS PHARMACEUTICALS INC